Corvus Pharmaceuticals (CRVS) Accumulated Depreciation & Amortization (2022 - 2025)
Corvus Pharmaceuticals (CRVS) has 4 years of Accumulated Depreciation & Amortization data on record, last reported at $79000.0 in Q3 2025.
- For Q3 2025, Accumulated Depreciation & Amortization rose 295.0% year-over-year to $79000.0; the TTM value through Sep 2025 reached $79000.0, up 295.0%, while the annual FY2024 figure was $100000.0, 50.0% down from the prior year.
- Accumulated Depreciation & Amortization reached $79000.0 in Q3 2025 per CRVS's latest filing, up from $29000.0 in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $4.3 million in Q1 2022 and bottomed at $20000.0 in Q3 2024.
- Average Accumulated Depreciation & Amortization over 4 years is $394933.3, with a median of $79000.0 recorded in 2025.
- Peak YoY movement for Accumulated Depreciation & Amortization: crashed 98.69% in 2023, then skyrocketed 295.0% in 2025.
- A 4-year view of Accumulated Depreciation & Amortization shows it stood at $400000.0 in 2022, then tumbled by 50.0% to $200000.0 in 2023, then tumbled by 50.0% to $100000.0 in 2024, then dropped by 21.0% to $79000.0 in 2025.
- Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $79000.0 in Q3 2025, $29000.0 in Q2 2025, and $22000.0 in Q1 2025.